R&D at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's R&D?
- Enliven Therapeutics (ELVN) reported R&D of $20.69M in Q1 2026.
- How has Enliven Therapeutics's R&D changed year-over-year?
- Enliven Therapeutics's R&D decreased by 16.9% year-over-year, from $24.9M to $20.69M.
- What is the long-term trend for Enliven Therapeutics's R&D?
- Over 4 years (2021 to 2025), Enliven Therapeutics's R&D has grown at a 22.2% compound annual growth rate (CAGR), from $38.44M to $85.86M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.